Clinical stage pharmaceutical company Quoin Pharmaceuticals Ltd (NASDAQ:QNRX) announced on Tuesday that it plans to initiate a clinical study evaluating QRX003 in a paediatric patient with Peeling Skin Syndrome (PSS) in New Zealand.

QRX003 is a topical lotion targeting skin inflammation and barrier disruption.

PSS is a rare genetic skin disorder with no approved treatment, causing severe pain and chronic itching.

Quoin is also conducting two late-stage clinical trials for QRX003 in Netherton Syndrome.